The value of PSA, free-to-total PSA ratio and PSA density in the prediction of pathologic stage for clinically localized prostate cancer
- PMID: 16307332
- DOI: 10.1007/s11255-005-0921-x
The value of PSA, free-to-total PSA ratio and PSA density in the prediction of pathologic stage for clinically localized prostate cancer
Abstract
Objective: The ability of prostate-specific antigen (PSA), free/total PSA and PSA density to predict the pathologic stage in prostate cancer has not been clear yet. In this study, we evaluated the value of PSA subgroups in the prediction of pathologic stage after radical prostatectomy.
Methods: A total of 42 subjects 55-78-years-old who underwent radical retropubic prostatectomy were included in the study. Preoperative PSA, free/total PSA and PSA density (PSAD) values were compared according to the pathologic stages of radical prostatectomy specimens. Receiver operating characteristics (ROC) curves were measured for each parameter.
Results: The clinical stage that was estimated for all patients was between T1N0M0 and T2bN0M0. Pathologic examination revealed organ-confined disease in 18 patients. The area under curve (AUC) for organ confinement was 0.553 for PSA, 0.446 for free/total PSA ratio and 0.706 for PSAD. Cut-off values providing the best sensitivity and specificity in ROC analysis for PSA, free/total PSA and PSAD were 7.1, 0.15, and 0.17, respectively (likelihood ratio: 0.9, 1 and 2). The positive predictive values at these cut-off values were 0.54, 0.56, and 0.70, respectively. Only PSAD cut-off values was found statistically borderline significant for predicting organ-confined disease.
Conclusion: While PSAD is more helpful than PSA and free/total PSA ratio for prediction of organ-confined disease, none of these parameters are significant predictor of pathologic stage for clinically localized prostate cancer.
Similar articles
-
Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.Prostate. 2003 Jun 15;56(1):23-9. doi: 10.1002/pros.10239. Prostate. 2003. PMID: 12746843
-
The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.BJU Int. 2012 Jul;110(1):36-42. doi: 10.1111/j.1464-410X.2011.10681.x. Epub 2011 Nov 15. BJU Int. 2012. PMID: 22085203
-
Inadequacy of free prostate-specific antigen parameters in the prediction of pathologic extent of prostate cancer in Japanese men.Urology. 1998 Aug;52(2):230-6. doi: 10.1016/s0090-4295(98)00179-4. Urology. 1998. PMID: 9697787
-
The use of percent free prostate specific antigen for staging clinically localized prostate cancer.J Urol. 1998 Apr;159(4):1238-42. J Urol. 1998. PMID: 9507844 Review.
-
Prostate cancer: emerging concepts. Part I.Ann Intern Med. 1996 Jul 15;125(2):118-25. doi: 10.7326/0003-4819-125-2-199607150-00008. Ann Intern Med. 1996. PMID: 8678366 Review.
Cited by
-
PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5-10.0 ng ml (-1) and 10.1-20.0 ng ml (-1) : a multicenter study.Asian J Androl. 2015 May-Jun;17(3):503-7. doi: 10.4103/1008-682X.142129. Asian J Androl. 2015. PMID: 25475661 Free PMC article.
-
Multiplexed Prostate Cancer Companion Diagnostic Devices.Sensors (Basel). 2021 Jul 24;21(15):5023. doi: 10.3390/s21155023. Sensors (Basel). 2021. PMID: 34372259 Free PMC article. Review.
-
Transition zone prostate specific antigen density improves prostate cancer detection in Iranian men.Nephrourol Mon. 2015 Mar 20;7(2):e26752. doi: 10.5812/numonthly.26752. eCollection 2015 Mar. Nephrourol Mon. 2015. PMID: 25821749 Free PMC article.
-
PSA density is superior than PSA and Gleason score for adverse pathologic features prediction in patients with clinically localized prostate cancer.Can Urol Assoc J. 2012 Feb;6(1):46-50. doi: 10.5489/cuaj.11079. Can Urol Assoc J. 2012. PMID: 22396369 Free PMC article.
-
Improved detection of prostate cancer using a magneto-nanosensor assay for serum circulating autoantibodies.PLoS One. 2019 Aug 12;14(8):e0221051. doi: 10.1371/journal.pone.0221051. eCollection 2019. PLoS One. 2019. PMID: 31404106 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous